Aim: Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver disorders associated with metabolic syndrome, and its prevalence has been on the rise. The pathogenesis of NAFLD has not yet been sufficiently elucidated due to the multifactorial nature of the disease, although the activation of macrophages/Kupffer cells is considered to be involved. We previously reported an animal model of NAFLD using Microminipigs™ (µMPs) fed high-fat diets containing cholesterol with or without cholic acid. The aim of this study was to investigate the phenotypic changes of macrophages that occur during the development of NAFLD.

Methods: Immunohistochemistry of macrophages, lymphocytes, and stellate cells was performed using liver samples, and the density of positive cells was analyzed.

Results: The number of Iba-1-positive macrophages increased with increasing cholesterol content in the diet. The numbers of CD163-positive macrophages and CD204-positive macrophages also increased with increasing cholesterol content in the diet; however, the proportion of CD204-positive macrophages among Iba-1-positive macrophages was significantly reduced by cholic acid supplementation.

Conclusion: The results suggest that lipid accumulation induced macrophage recruitment in swine livers, and that the number of M2-like macrophages increased at the early stage of NAFLD, while the number of M1-like macrophages increased at the late stage of NAFLD, resulting in a liver condition like non-alcoholic steatohepatitis. We provide evidence of the phenotypic changes that occur in macrophages during the development of NAFLD that has never been reported before using µMPs.

Key words: Macrophage, Fatty liver disease, NAFLD, NASH, Microminipig

Introduction

Non-alcoholic fatty liver disease (NAFLD) is one of the most common chronic liver disorders worldwide, particularly in the Middle East and South America\(^1\). The prevalence of NAFLD has increased in the general population, and in Japan, the overall prevalence of NAFLD was around 30% from 2009 to 2010\(^2,3\). Current epidemiological estimates indicate that NAFLD will soon be the leading causative liver disease of liver transplantation\(^4\). The spectrum of NAFLD ranges from non-alcoholic fatty liver (NAFL), hepatic steatosis without the presence of significant inflammation, to non-alcoholic steatohepatitis.
(NASH), a complex pattern with active lesions of hepatocyte injury, apoptosis, cell death, and inflammation in the absence of alcohol intake. NASH potentially progresses to liver cirrhosis and hepatocellular carcinoma. The major risk factors for NAFLD are obesity, type 2 diabetes mellitus, hyperlipidemia, hypertension, and metabolic syndrome; however, the pathogenesis of NASH is multifactorial and has not yet been sufficiently elucidated. Excess lipid accumulation in hepatocytes and subsequent hepatocellular injury, hepatic inflammation, and the activation of hepatic stellate cells (HSC) are induced by endoplasmic reticulum stress, oxidative stress, and inflammation activation in hepatocytes. This process is considered to be one of the causes of NAFLD/NASH pathogenesis. Macrophages (Kupffer cells) are the main population of inflammatory cells in the liver, and activated macrophages secrete several pro-inflammatory cytokines, including interleukin (IL)-1β, tumor necrosis factor-α, and IL-6. In a previous report, macrophage depletion ameliorated liver damage in a murine NASH model. This indicated that macrophage activation may be closely associated with the pathogenesis of NAFLD/NASH. Macrophage activation is broadly divided into two phenotypes; many researchers have reported that M1 and M2 macrophages have pro-inflammatory and anti-inflammatory functions, respectively, but the difference in functions between M1 and M2 macrophages remains controversial. Words such as “M1-like” or “M2-like” are used to explain the heterogeneity in macrophage phenotypes. The phenotypic change of macrophages into the M1-like phenotype has been reported in a mouse NAFLD/NASH model, and an increased number of M1-like macrophages has also been reported in NASH liver samples in a human study. However, the significance of M1-like macrophages in the pathogenesis of NAFLD/NASH remains unclear in humans.

We recently established an animal model using Microminipigs (µMPs) for studying hyperlipidemia and NAFLD. In this study, we tried to characterize the phenotype of macrophages/Kupffer cells according to the development of the pathological condition of NAFLD in the µMPs. We showed that lipid accumulated in the hepatocytes and macrophages, and that the number of macrophages attached to hepatic stellate cells (HSCs) increased with increasing severity of the liver condition. We also revealed changes in the numbers and phenotypes of macrophages that have never been reported before in swine.

### Methods

#### Animals

The swine and diets used were as described previously. The swine were fed a normal chow diet (NcD; Kodakara 73, Marubeni Nisshin Feed, Tokyo, Japan) or one of the special diets on a daily basis (3% of body weight/day) for 8 weeks. The special diets were high-fat diets with cholesterol (HcDs); they consisted of NcD supplemented with 12% lard (Miyoshi Oil & Fat, Tokyo, Japan) and 0.2%, 0.5%, or 1.5% cholesterol (Wako Pure Chemical, Osaka, Japan). Twenty-five µMPs were divided into five groups (n = 5 each) as follows: the 1) NcD group; 2) HcD (0.2% cholesterol) group; 3) HcD (0.5% cholesterol) group; 4) HcD (1.5% cholesterol) group; and 5) HcD (1.5% cholesterol) with 0.7% cholic acid (CA; Wako Pure Chemical) group.

#### Samples

Formalin-fixed paraffin-embedded µMP liver samples, which were prepared in a previous study, were used for hematoxylin and eosin staining, Gomori’s silver impregnation, and immunohistochemistry (IHC). All protocols were approved by the Ethics Committee of Animal Care and Experimentation, Kagoshima University, and were performed according to the Institutional Guidelines for Animal Experiments and the Laws (no. 105) and Notification (no. 6). For double-IHC, HistoGreen (green color) substrate was used.

#### IHC

Specimens were cut into 3-µm sections. For immunostaining, anti-Iba-1 (#019-19741, rabbit polyclonal, FUJIFILM Wako Pure Chemical Corp., Tokyo, Japan), anti-CD163 (#ab182422, rabbit monoclonal, clone EPR14336, Abcam, Cambridge, UK), and anti-CD204 (#KMU-MA01, mouse monoclonal, clone SRA-E5, Cosmo Bio, Tokyo, Japan) were used as the primary antibodies to detect macrophages. Anti-CD3 antibody (#413591, rabbit monoclonal, clone SP7, Nichirei Biosciences, Tokyo, Japan) was used as the primary antibody to detect lymphocytes. Anti-α-smooth muscle actin (#M0851, mouse monoclonal, clone 1A4, Agilent Technologies, Inc., Santa Clara, CA, USA) was used as the primary antibody to detect activated HSCs (myofibroblasts). The samples were incubated with horseradish peroxidase-labeled goat anti-mouse or rabbit secondary antibodies (#424131 for anti-mouse and #424141 for anti-rabbit, Histofine, Nichirei Biosciences). We visualized immunoreactions using a diaminobenzidine substrate kit. For double-IHC, HistoGreen (green color) substrate
All tests were two-sided, and we considered Wallis test to perform comparisons between groups.

Statistics

Institutes of Health, Bethesda, MD, USA).

The proportion of immunostained area per field and cells per group were measured and then compared. The size of macrophages was quantified by ImageJ 1.46 (National Institutes of Health, Bethesda, MD, USA).

Statistics

We used the Mann-Whitney U test and Kruskal-Wallis test to perform comparisons between groups. All tests were two-sided, and we considered P values < 0.050 to be statistically significant. Statistical analyses were performed with GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA).

Results

The Density of Macrophages Increased with Increasing Cholesterol Content in the Diet and CA Administration

Hepatic steatosis could be seen in the HcD (0.5% cholesterol) group to the HcD (1.5% cholesterol) group, and hepatic lobular inflammation and foamy macrophages were seen in the HcD (1.5% cholesterol) group. Hepatocyte ballooning, the characteristic finding of NASH, was seen only in the HcD (1.5% cholesterol) with CA group (Fig. 1A). We then performed IHC for Iba-1, a pan-macrophage marker, to detect macrophages/Kupffer cells in the livers. The number and staining area of Iba-1-positive macrophages increased with increasing content of cholesterol in the diet, and they were significantly elevated by CA administration (Fig. 1A and 1B). The size of macrophages also increased with increasing cholesterol content in the diet (Fig. 1B). These results suggested that macrophage accumulation is stimulated by cholesterol intake, and that the level of accumulation is dependent on the concentration of cholesterol in the daily diet.

The Proportion of M2-Like Macrophages was Reduced by CA Administration

CD163 and CD204 are well-known M2-like markers that are specifically expressed on macrophages. To investigate the M1/M2 balance in the livers of µMPs, we performed IHC of Iba-1, CD163, and CD204 using serial sections. Interestingly, CD163- and CD204 expression in Iba-1-positive macrophages were decreased by CA administration (Fig. 2A). The densities and percentages of CD163-positive macrophages and CD204-positive macrophages increased with increasing cholesterol content in the groups without CA; however, CA administration reduced the densities and percentages of CD163-positive macrophages and CD204-positive macrophages (Fig. 2B and 2C). In particular, a statistically significant reduction in the proportion of CD204-positive macrophages among Iba-1-positive macrophages was found (P = 0.0367). However, similar to the Iba-1-positive macrophages, the sizes of CD163-positive macrophages and CD204-positive macrophages also increased with increasing cholesterol content in the diet (Fig. 2B and 2C). The results suggested that macrophages changed to a non-M2-like (M1-like) phenotype with increasing cholesterol content and the addition of CA.

The Number of Iba-1-Positive Macrophages Attached to Activated HSCs Increased with Increasing Cholesterol Content in the Diet and CA Administration

Progressive fibrosis is the hallmark of NASH, and HSCs are responsible for fibrogenesis in liver disease. To assess perisinusoidal fibrosis, we stained the sections using Gomori’s silver impregnation staining technique. There was no significant difference in perisinusoidal fibrosis between the NcD group, HcD (0.2% cholesterol) group, and HcD (0.5% cholesterol) group; however, perisinusoidal fibrosis was more evident in the HcD (1.5% cholesterol) group and HcD (1.5% cholesterol) with CA group (Fig. 3). Next, to explore the microenvironmental interactions between macrophages, HSCs, and immune cells, we performed double-IHC for macrophages and activated HSCs, and triple-IHC for macrophages, activated HSCs, and lymphocytes. The number of αSMA-positive activated HSCs increased with increasing cholesterol content and CA administration (Fig. 4A, 4B). Double-IHC suggested that the number of Iba-1-positive macrophages attached to αSMA-positive activated HSCs increased with increasing cholesterol content and CA administration; however, the number of CD163-positive macrophages attached to αSMA-positive activated HSCs seemed not to be changed with increasing cholesterol content and CA administration.
CD204 is generally known to be an essential component for foam cell formation\(^1\). Anti-inflammatory M2 macrophages have been reported to be more sensitive to foam cell formation than inflammatory M1 macrophages\(^1\), indicating that foam cell formation occurs predominantly in anti-inflammatory M2 macrophages. Scavenger receptors bind and internalize modified plasma low-density lipoproteins (LDL) and high-density lipoproteins, causing cholesterol ester accumulation in the macrophages. M2 macrophages then become pro-inflammatory (M1-like phenotype) upon exposure to oxidized LDL\(^1\). It has been reported that exposure to oxidized LDL induced M1-like polarization by suppressing Krüppel-like factor 2\(^1\). In addition, macrophages that newly invade the liver due to the release of chemotactic factors are monocyte-derived CD163-negative cells\(^8, 14\). Therefore, it may be considered that the ratio of M2-like

**Discussion**

In this study, we investigated the changes in macrophage characteristics using µMPs fed a high-fat/high-cholesterol diet with or without CA as an animal model of NAFLD. We found that the expression of CD163/CD204 and the proportions of CD163-positive macrophages and CD204-positive macrophages among Iba-1-positive macrophages were reduced in the HcD (1.5% cholesterol) with CA group. CD163 and CD204, known as M2 markers, are expressed in normal tissue-resident macrophages (liver Kupffer cells)\(^14, 15\). In particular, the scavenger receptor SR-A (CD204) is generally known to be an essential component for foam cell formation\(^10\). Anti-inflammatory M2 macrophages have been reported to be more sensitive to foam cell formation than inflammatory M1 macrophages\(^1\), indicating that foam cell formation occurs predominantly in anti-inflammatory M2 macrophages. Scavenger receptors bind and internalize modified plasma low-density lipoproteins (LDL) and high-density lipoproteins, causing cholesterol ester accumulation in the macrophages. M2 macrophages then become pro-inflammatory (M1-like phenotype) upon exposure to oxidized LDL\(^18, 19\). It has been reported that exposure to oxidized LDL induced M1-like polarization by suppressing Krüppel-like factor 2\(^1\). In addition, macrophages that newly invade the liver due to the release of chemotactic factors are monocyte-derived CD163-negative cells\(^8, 14\). Therefore, it may be considered that the ratio of M2-like
Macrophages decreased not only because M2-like macrophages (Kupffer cells) changed their polarity to be M1-like, but also because monocytes that expressed low levels of CD163 and CD204 invaded.

The contribution of macrophages to the development of NAFLD has been reported by many groups. In this study, high-fat diets (12% lard) with cholesterol were fed, and lard consists of fatty acids. Excess lipids (fatty acids and cholesterol) are responsible for the pathogenesis of NAFLD. Excess lipids can contribute to the formation of lipotoxic lipids in hepatocytes, which leads to ER stress, oxidative stress, and inflammasome activation. These processes cause hepatic injury, and the production of cytokines (e.g., IL-1β, IL-6, IL-18, tumor necrosis factor-α, and transforming growth factor-β) and macrophage-recruiting chemokines (e.g., CCL2 and CXCL10). Activated macrophages and HSCs also produce various chemokines for increasing macrophage recruitment. Macrophages are activated into M1-like macrophages by the uptake of lipids, and the activated M1-like macrophages produce pro-inflammatory cytokines that can cause hepatocyte steatosis and hepatocellular damage. M2-like macrophages produce anti-inflammatory mediators (e.g., IL-10), and are considered to play a protective role in the development of metabolic diseases. In atherosclerosis, M2-like macrophages are dominant at the early stage, and the macrophages preferentially shift to the M1-like phenotype at the late stage.
increased number of Iba-1-positive macrophages attached to HSCs (Fig. 4A and B). HSCs are the cells most responsible for fibrogenesis. Perisinusoidal collagen deposition is a histological finding of NASH. Injury or stressed hepatocytes and activated macrophages induce the activation of HSCs into collagen-progression toward a NASH-like liver condition. The development of NAFLD may occur as a consequence of an imbalance between M1-like and M2-like activated macrophages in the liver.

We demonstrated that there was an increased number of αSMA-positive activated HSCs and an increased number of Iba-1-positive macrophages attached to HSCs (Fig. 4A and B). HSCs are the cells most responsible for fibrogenesis. Perisinusoidal collagen deposition is a histological finding of NASH.
producing myofibroblasts. By double-IHC, we demonstrated the crosstalk between Iba-1-positive macrophages and activated HSCs; however, the crosstalk between CD163-positive macrophages and activated HSCs was not enhanced. CD163-negative cells consist of Kupffer cells with a pro-inflammatory phenotype, and monocytes recruited from the bone marrow may be responsible for the activation of HSCs and act as pro-fibrotic macrophages. Macrophages and HSCs are closely related to inflammatory cells, such as lymphocytes and neutrophils, in the pathogenesis of NAFLD, and we could show the microenvironmental interactions by triple-IHC.

We recently established a swine model for the investigation of atherosclerosis and NAFLD. Although foamy macrophages were found in groups fed high-fat/high-cholesterol diets, hepatocyte ballooning was found only in the group supplemented with CA in this study. Hepatocyte ballooning is one of the most important pathological findings in NAFLD, and we could show the microenvironmental interactions by triple-IHC.

We have no conflicts of interest to declare.

Acknowledgements

This work was supported in part by a grant from the Kodama Memorial Fund for Medical Research, Kagoshima, Japan (to S.Y.), Health Labour Sciences research Grant (No. 33361105) from the Ministry of Health, Labour and Welfare of Japan (to A.T.), the Adaptable and Seamless Technology Transfer Program Grant (A-Step No. AS2316907E) from the Ministry of Education, Culture, Sports, Science and Technology, Tokyo, Japan (to A.T. and H.K.), the SENSHIN Medical Research Foundation (to H.K.), and KAKENHI (16H05162, to Y.K.).

The authors are grateful to Ms. Takana Motoyoshi (K.I. Stainer Inc.) for assistance with immunostaining analysis.

A Conflict of Interest Statement

We have no conflicts of interest to declare.

References

1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M: Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016; 64: 73-84
2. Arrese M, Cabrera D, Kalergis AM, Feldstein AE: Innate Immunity and Inflammation in NAFLD/NASH. Dig Dis Sci, 2016; 61: 1294-1303
3. Tsuchida T, Friedman SL: Mechanisms of hepatic stellate cell activation. Nat Rev Gastroenterol Hepatol, 2017; 14: 397-411
4. Oates JR, McKell MC, Moreno-Fernandez ME, Damen JA: Mechanisms of NAFLD development and therapeutic strategies. Nat Med, 2018; 24: 908-922
5. Bedossa P: Pathology of non-alcoholic fatty liver disease. Liver Int, 2017; 37 Suppl 1: 85-89
6. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, Shirdosh M: Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol, 2011; 9: 524-530.e521; quiz e560
7. Friedman SL, Neuschwander-Tetri BA, Rinella M, Sanyal AJ: Mechanisms of NAFLD development and therapeutic strategies. Nat Med, 2018; 24: 908-922
8. Komohara Y, Fujiwara Y, Ohnishi K, Shiraishi D, Takeya M: Contribution of Macrophage Polarization to Metabolic Diseases. J Atheroscler Thromb, 2016; 23: 10-17
9. Tosello-Tramont AC, Landes SG, Nguyen V, Novo-brantseva TI, Hahn YS: Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-alpha production. J Biol Chem, 2012; 287: 40161-40172
10. Zhang X, Fan L, Wu J, Xu H, Leung WY, Fu K, Wu J, Liu K, Man K, Yang X, Han J, Ren J, Yu J: Macrophage p38alpha promotes nutritional steatohepatitis through M1 polarization. J Hepatol, 2019; 71: 163-174
11. Fukushima H, Yamashina S, Arakawa A, Taniguchi G, Aoyama T, Uchiyama A, Kon K, Ikejima K, Watanabe S: Formation of p62-positive inclusion body is associated with the development of novel therapies.
with macrophage polarization in non-alcoholic fatty liver disease. Hepatol Res, 2018; 48: 757-767
12) Yamada S, Kawaguchi H, Yamada T, Guo X, Matsuo K, Hamada T, Miura N, Tasaki T, Tanimoto A: Cholic Acid Enhances Visceral Adiposity, Atherosclerosis and Nonalcoholic Fatty Liver Disease in Microminipigs. J Atheroscler Thromb, 2017; 24: 1150-1166
13) Nakagawa T, Ohashi K, Kosaki Y, Saito Y, Horlad H, Fujiwara Y, Takeya M, Komohara Y: Optimum immunohistochemical procedures for analysis of macrophages in human and mouse formalin fixed paraffin-embedded tissue samples. J Clin Exp Hematop, 2017; 57: 31-36
14) Fabriek BO, Dijkstra CD, van den Berg TK: The macrophage scavenger receptor CD163. Immunobiology, 2005; 210: 153-160
15) Kiyanagi T, Iwabuchi K, Shimada K, Hirose K, Miyazaki T, Sumiyoshi K, Ishihara C, Nakayama H, Masuda H, Mokuno H, Sato S, Daida H: Involvement of cholesterol-enriched microdomains in class A scavenger receptor-mediated responses in human macrophages. Atherosclerosis, 2011; 215: 60-69
16) Moore KJ, Freeman MW: Scavenger receptors in atherosclerosis: beyond lipid uptake. Arterioscler Thromb Vasc Biol, 2006; 26: 1702-1711
17) van Tits L, Stienstra R, van Lent PL, Netea MG, Joosten LA, Stalenhofen AF: Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Krüppel-like factor 2. Atherosclerosis, 2011; 214: 345-349
18) Goldstein JL, Ho YK, Basu SK, Brown MS: Binding site on macrophages that mediates uptake and degradation of acetylated low density lipoprotein, producing massive cholesterol deposition. Proc Natl Acad Sci U S A, 1979; 76: 333-337
19) Kelley JL, Ozment TR, Li C, Schweitzer JB, Williams DL: Scavenger receptor-A (CD204): a two-edged sword in health and disease. Crit Rev Immunol, 2014; 34: 241-261
20) Obstfeld AE, Sugaru E, Thearle M, Francisco AM, Gayet C, Ginsberg HN, Rice E, Ferrante AW, Jr.: C-C chemokine receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis. Diabetes, 2010; 59: 916-925
21) Holt AP, Haughton EL, Lalor PF, Filer A, Buckley CD, Adams DH: Liver myofibroblasts regulate infiltration and hepatic steatosis. Diabetes, 2010; 59: 916-925
22) Duewell P, Kono H, Rayner KJ, Siros CM, Vladimir G, Bauerfeind FG, Abela GS, Franchi L, Nunez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E: NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature, 2010; 464: 1357-1361
23) Colin S, Chinetti-Gbaguidi G, Staels B: Macrophage phenotypes in atherosclerosis. Immunol Rev, 2014; 262: 153-166
24) Gordon S, Martinez FO: Alternative activation of macrophages: mechanism and functions. Immunity, 2010; 32: 593-604
25) Gordon S: Alternative activation of macrophages. Nat Rev Immunol, 2003; 3: 23-35
26) Usman A, Ribatti D, Sadat U, Gillard JH: From Lipid Retention to Immune-Mediate Inflammation and Associated Angiogenesis in the Pathogenesis of Atherosclerosis. J Atheroscler Thromb, 2015; 22: 739-749
27) Kallou-Laschet J, Varthaman A, Fornasa G, Compain P, Gaston AT, Clement M, Dussiot M, Levillain O, Graff-Dubois S, Nicoletti A, Caligiuri G: Macrophage plasticity in experimental atherosclerosis. PLoS One, 2010; 5: e8852
28) Ramachandran P, Iredale JP: Macrophages: central regulators of hepatic fibrogenesis and fibrosis resolution. J Hepatol, 2012; 56: 1417-1419
29) Nati M, Haddad D, Birkenfeld AL, Koch CA, Chavakis T, Chatzigeorgiou A: The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH). Rev Endocr Metab Disord, 2016; 17: 29-39
30) Ilan Y, Shailubhai K, Sanyal A: Immunotherapy with oral administration of humanized anti-CD3 monoclonal antibody: a novel gut-immune system-based therapy for metaflammation and NASH. Clin Exp Immunol, 2018; 193: 275-283
31) Van Herck MA, Weyler J, Kwanten WJ, Dirinck EL, De Winter BY, Francue SM, Vonghia L: The Differential Roles of T Cells in Non-alcoholic Fatty Liver Disease and Obesity. Front Immunol, 2019; 10: 82
32) Kawaguchi H, Yamada T, Miura N, Ayaori M, Uoto-Kondo H, Ikegawa M, Noguchi M, Wang KY, Izumi H, Tanimoto A: Rapid development of atherosclerosis in the world's smallest Microminipig fed a high-fat/high-cholesterol diet. J Atheroscler Thromb, 2014; 21: 186-203
33) Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR: Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol, 1999; 94: 2467-2474
34) Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology, 1999; 116: 1413-1419
35) Younossi ZM, Stepanova M, Rafiq N, Makhlouf H, Younossi Z, Agrawal R, Goodman Z: Pathologic criteria for nonalcoholic steatohepatitis: interpretrogreement and ability to predict liver-related mortality. Hepatology, 2011; 53: 1874-1882
36) Allen K, Jaeschke H, Copple BL: Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol, 2011; 178: 175-186
37) Sokol RJ, Winklhofer-Roob BM, Devereaux MW, McKim JM, Jr.: Generation of hydroperoxides in isolated rat hepatocytes and hepatic mitochondria exposed to hydrophobic bile acids. Gastroenterology, 1995; 109: 1249-1256